Latest filing published 04 May 2021 for Werewolf Therapeutics, Inc., €5.3M.
Insider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Alon Lazarus: trading record in brief
Filings by Alon Lazarus span 2 companies, the busiest being Keros Therapeutics, Inc. and Werewolf Therapeutics, Inc. The record holds 7 filings, for trades running from 13 April 2020 to 4 May 2021.
No open-market sale appears; the market trades are 2 purchases worth €7.1M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2021, the count stands at 1 purchase and no sales.
On 4 May 2021 came the latest disclosure, an open-market purchase for €5.3M in Werewolf Therapeutics, Inc. Most trades are made public on the day they happen. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Alon Lazarus
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 400,000 shares@ US$16.00100.0% of flowCommon StockSEC:0000899243-21-018111:2Canonical exit: 2 Aug 2021 (T+90)
- 410,717 sharesCommon StockSEC:0000899243-21-018111:1
- 1,235,917 sharesCommon StockSEC:0000899243-21-018111:0
- 343,270 sharesCommon StockSEC:0001209191-20-024228:1
- 167,537 sharesCommon StockSEC:0001209191-20-024228:2
- 1,382,295 sharesCommon StockSEC:0001209191-20-024228:0
- ▲
Same trade as the filing by Arkin Bio Ventures Limited Partnership, counted once
2M USD37SEC120,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001209191-20-024228:3Canonical exit: 12 Jul 2020 (T+90)
7 of 5 declarations
